News

Meta-analysis of other randomized controlled trials have shown that vitamin D supplementation reduces the risk of acute respiratory infections and exacerbations of asthma.

Ocrelizumab demonstrated superiority to or comparability with 14 other disease-modifying therapies currently approved by the European Medicines Agency.

The FDA has responded to the Janssen Pharmaceutical company's sNDA with a request for more data.

Improvements in muscle and cardiac function were observed for 18 months in tested mice.

This is the first generic approval of the tablet form of vigabatrin, which is indicated for treating focal seizures in patients with epilepsy.

The FDA has approved a scalpel-free method for the treatment of patients with Parkinson disease who experience tremors and are medication-resistant.

Currently in phase 1 testing, ACX-362E is being developed as a narrow spectrum antibiotic for the treatment of Clostridium difficile infection.

A noninvasive and age-specific test could facilitate surgery for focal epilepsy in children.

Success with metronidazole was more likely in patients 65 years and under but was about the same as with vancomycin in those patients.

The antipsyhoctic could receive a new indication in 2019, and though the field of bipolar disorder care is far from perfect, it should improve with this addition.

Mapping techniques for tracking sexually transmitted bacterial disease can also identify core areas of HCV infection to guide treatment interventions.

A team of clinicians and investigators are working to define core outcome sets that it hopes will increase the utility of randomized clinical trials and stimulate research.

The FDA has approved cabozantinib (Cabometyx) for the treatment of patients with hepatocellular carcinoma who previously received sorafenib (Nexavar).

The 2016-2017 influenza season, dominated by the H3N2 strain, saw an uptick in the number of children experiencing neurological manifestations of influenza.

Study finds having a vaccinated child in the household was associated with 21% lower prevalence of sick leave usage by household adults.

Differing therapies, inaccurate regimens, missed diagnoses—issues can compound quickly for patients with PD seeking care for something else.

About half of all patients with COPD suffer from serious adverse events following a hospital discharge, yet physicians cannot accurately distinguish which are at risk.

The repeated dose vaccine from Sanofi Pasteur was assessed in 1300-plus patients aged 18 to 64. Currently, about 75% of US adults have not received a Tdap vaccination.

Only patients with very serious, life-threatening conditions with a risk/benefit ratio is acceptable for use of the therapy at this time.

The imaging platform is now the only of its kind approved for optimizing blood clot removal in the US.

A recent study found a link between electronic nicotine delivery systems and asthma symptoms.

The Amplatzer Piccolo Occluder is implanted via catheter to repair patent ductus arteriosus in newborns weighing as little as 2 pounds.

Some of the most common symptoms of COPD drive anxiety in its patients. An England-based study sought out a cost-effective response.

People in high-risk categories should be tested and begin antiviral treatment promptly if they are hospitalized with flu symptoms, the Infectious Diseases Society of America recommends.

New research finds participants don’t always accurately report—or know—their HIV status when enrolling in studies.

Why it's critical for physicians to remember that patients may not be as well-versed on the particularities of conceiving a child.

The new C difficile guidelines highlight improvements in diagnosing the condition and treating with newer options like fidaxomicin, vancomycin, and fecal microbiota transplantation.

Flibanserin, a once-daily oral drug, is the only marketed therapy for female sexual dysfunction. Are more options needed?